Search

Your search keyword '"Pollock, Pamela M"' showing total 302 results
Start Over Author "Pollock, Pamela M"
302 results on '"Pollock, Pamela M"'

3. Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer

Author

Bonazzi, Vanessa F., Kondrashova, Olga, Smith, Deborah, Nones, Katia, Sengal, Asmerom T., Ju, Robert, Packer, Leisl M., Koufariotis, Lambros T., Kazakoff, Stephen H., Davidson, Aimee L., Ramarao-Milne, Priya, Lakis, Vanessa, Newell, Felicity, Rogers, Rebecca, Davies, Claire, Nicklin, James, Garrett, Andrea, Chetty, Naven, Perrin, Lewis, Pearson, John V., Patch, Ann-Marie, Waddell, Nicola, and Pollock, Pamela M.

Published
2022
Full Text
View/download PDF

5. A humanized orthotopic tumor microenvironment alters the bone metastatic tropism of prostate cancer cells

Author

McGovern, Jacqui A., Bock, Nathalie, Shafiee, Abbas, Martine, Laure C., Wagner, Ferdinand, Baldwin, Jeremy G., Landgraf, Marietta, Lahr, Christoph A., Meinert, Christoph, Williams, Elizabeth D., Pollock, Pamela M., Denham, Jim, Russell, Pamela J., Risbridger, Gail P., Clements, Judith A., Loessner, Daniela, Holzapfel, Boris M., and Hutmacher, Dietmar W.

Published
2021
Full Text
View/download PDF

7. Potential Synergy: Rural School Districts and International Student Programs

Author

Casto, Hope G., Steinhauer, Alexandra, and Pollock, Pamela M.

Abstract

Many rural school districts face declining enrollments. A few districts have taken the unusual path of recruiting international students in order to boost their enrollments. This study examines a community using this strategy and the resulting financial, academic, and social situations for the school, community, and students, both local and international. The program has two goals: to increase both enrollment and diversity in the school. The benefits and challenges are discussed in light of the social and academic spheres of the school experience. The future of the program is considered, especially in connection to community fears of school closure or consolidation. Issues of professional development for teachers and programming for students are described. Recommendations for districts considering an international student program are included. This work contributes to a better understanding of the potential synergy between schools and communities. (Contains 1 footnote.)

Published
2012

8. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative

Author

Auguste, Aurélie, Genestie, Catherine, De Bruyn, Marco, Adam, Julien, Le Formal, Audrey, Drusch, Françoise, Pautier, Patricia, Crosbie, Emma J., MacKay, Helen, Kitchener, Henry C., Powell, Melanie, Pollock, Pamela M., Mileshkin, Linda, Edmondson, Richard J., Nout, Remi, Nijman, Hans W., Creutzberg, Carien L., Bosse, Tjalling, and Leary, Alexandra

Published
2018
Full Text
View/download PDF

12. Data from Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma

Author

Gartside, Michael G., primary, Chen, Huaibin, primary, Ibrahimi, Omar A., primary, Byron, Sara A., primary, Curtis, Amy V., primary, Wellens, Candice L., primary, Bengston, Ana, primary, Yudt, Laura M., primary, Eliseenkova, Anna V., primary, Ma, Jinghong, primary, Curtin, John A., primary, Hyder, Pilar, primary, Harper, Ursula L., primary, Riedesel, Erica, primary, Mann, Graham J., primary, Trent, Jeffrey M., primary, Bastian, Boris C., primary, Meltzer, Paul S., primary, Mohammadi, Moosa, primary, and Pollock, Pamela M., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Data from Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma

Author

Gartside, Michael G., primary, Chen, Huaibin, primary, Ibrahimi, Omar A., primary, Byron, Sara A., primary, Curtis, Amy V., primary, Wellens, Candice L., primary, Bengston, Ana, primary, Yudt, Laura M., primary, Eliseenkova, Anna V., primary, Ma, Jinghong, primary, Curtin, John A., primary, Hyder, Pilar, primary, Harper, Ursula L., primary, Riedesel, Erica, primary, Mann, Graham J., primary, Trent, Jeffrey M., primary, Bastian, Boris C., primary, Meltzer, Paul S., primary, Mohammadi, Moosa, primary, and Pollock, Pamela M., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table 1 from Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes

Author

Pinnix, Chelsea C., primary, Lee, John T., primary, Liu, Zhao-Jun, primary, McDaid, Ronan, primary, Balint, Klara, primary, Beverly, Levi J., primary, Brafford, Patricia A., primary, Xiao, Min, primary, Himes, Benjamin, primary, Zabierowski, Susan E., primary, Yashiro-Ohtani, Yumi, primary, Nathanson, Katherine L., primary, Bengston, Ana, primary, Pollock, Pamela M., primary, Weeraratna, Ashani T., primary, Nickoloff, Brian J., primary, Pear, Warren S., primary, Capobianco, Anthony J., primary, and Herlyn, Meenhard, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure S3 from Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells

Author

Qin, Jian-Zhong, primary, Ziffra, Jeffrey, primary, Stennett, Lawrence, primary, Bodner, Barbara, primary, Bonish, Brian K., primary, Chaturvedi, Vijaya, primary, Bennett, Frank, primary, Pollock, Pamela M., primary, Trent, Jeffrey M., primary, Hendrix, Mary J.C., primary, Rizzo, Paola, primary, Miele, Lucio, primary, and Nickoloff, Brian J., primary

Published
2023
Full Text
View/download PDF

23. Data from Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes

Author

Pinnix, Chelsea C., primary, Lee, John T., primary, Liu, Zhao-Jun, primary, McDaid, Ronan, primary, Balint, Klara, primary, Beverly, Levi J., primary, Brafford, Patricia A., primary, Xiao, Min, primary, Himes, Benjamin, primary, Zabierowski, Susan E., primary, Yashiro-Ohtani, Yumi, primary, Nathanson, Katherine L., primary, Bengston, Ana, primary, Pollock, Pamela M., primary, Weeraratna, Ashani T., primary, Nickoloff, Brian J., primary, Pear, Warren S., primary, Capobianco, Anthony J., primary, and Herlyn, Meenhard, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Methods and Materials from Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes

Author

Pinnix, Chelsea C., primary, Lee, John T., primary, Liu, Zhao-Jun, primary, McDaid, Ronan, primary, Balint, Klara, primary, Beverly, Levi J., primary, Brafford, Patricia A., primary, Xiao, Min, primary, Himes, Benjamin, primary, Zabierowski, Susan E., primary, Yashiro-Ohtani, Yumi, primary, Nathanson, Katherine L., primary, Bengston, Ana, primary, Pollock, Pamela M., primary, Weeraratna, Ashani T., primary, Nickoloff, Brian J., primary, Pear, Warren S., primary, Capobianco, Anthony J., primary, and Herlyn, Meenhard, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 1 from Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes

Author

Pinnix, Chelsea C., primary, Lee, John T., primary, Liu, Zhao-Jun, primary, McDaid, Ronan, primary, Balint, Klara, primary, Beverly, Levi J., primary, Brafford, Patricia A., primary, Xiao, Min, primary, Himes, Benjamin, primary, Zabierowski, Susan E., primary, Yashiro-Ohtani, Yumi, primary, Nathanson, Katherine L., primary, Bengston, Ana, primary, Pollock, Pamela M., primary, Weeraratna, Ashani T., primary, Nickoloff, Brian J., primary, Pear, Warren S., primary, Capobianco, Anthony J., primary, and Herlyn, Meenhard, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure Legends 1-2 from Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes

Author

Pinnix, Chelsea C., primary, Lee, John T., primary, Liu, Zhao-Jun, primary, McDaid, Ronan, primary, Balint, Klara, primary, Beverly, Levi J., primary, Brafford, Patricia A., primary, Xiao, Min, primary, Himes, Benjamin, primary, Zabierowski, Susan E., primary, Yashiro-Ohtani, Yumi, primary, Nathanson, Katherine L., primary, Bengston, Ana, primary, Pollock, Pamela M., primary, Weeraratna, Ashani T., primary, Nickoloff, Brian J., primary, Pear, Warren S., primary, Capobianco, Anthony J., primary, and Herlyn, Meenhard, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 2 from Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes

Author

Pinnix, Chelsea C., primary, Lee, John T., primary, Liu, Zhao-Jun, primary, McDaid, Ronan, primary, Balint, Klara, primary, Beverly, Levi J., primary, Brafford, Patricia A., primary, Xiao, Min, primary, Himes, Benjamin, primary, Zabierowski, Susan E., primary, Yashiro-Ohtani, Yumi, primary, Nathanson, Katherine L., primary, Bengston, Ana, primary, Pollock, Pamela M., primary, Weeraratna, Ashani T., primary, Nickoloff, Brian J., primary, Pear, Warren S., primary, Capobianco, Anthony J., primary, and Herlyn, Meenhard, primary

Published
2023
Full Text
View/download PDF

35. Additional file 1 of Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer

Author

Bonazzi, Vanessa F., Kondrashova, Olga, Smith, Deborah, Nones, Katia, Sengal, Asmerom T., Ju, Robert, Packer, Leisl M., Koufariotis, Lambros T., Kazakoff, Stephen H., Davidson, Aimee L., Ramarao-Milne, Priya, Lakis, Vanessa, Newell, Felicity, Rogers, Rebecca, Davies, Claire, Nicklin, James, Garrett, Andrea, Chetty, Naven, Perrin, Lewis, Pearson, John V., Patch, Ann-Marie, Waddell, Nicola, and Pollock, Pamela M.

Abstract

Additional file 1: Supplementary Methods, Supplementary Tables 1-3,5 and Supplementary Figures.

Published
2022
Full Text
View/download PDF

39. Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma.

Author

Sengal, Asmerom T, Smith, Deborah, Snell, Cameron E, Leung, Samuel, Talhouk, Aline, Williams, Elizabeth D, McAlpine, Jessica N, and Pollock, Pamela M

Subjects
ENDOMETRIAL cancer, FIBROBLAST growth factor 2, FIBROBLAST growth factor receptors, ENDOMETRIUM, NUCLEIC acid hybridization, BIOMARKERS
Abstract

Endometrial carcinoma (EC) is the most common gynecological malignancy and fibroblast growth factor receptor 2 (FGFR2) is a frequently dysregulated receptor tyrosine kinase. FGFR2b and FGFR2c are the two main splice isoforms of FGFR2 and are normally localized in epithelial and mesenchymal cells, respectively. Previously, we demonstrated that FGFR2c mRNA expression was associated with aggressive tumor characteristics, shorter progression‐free survival (PFS), and disease‐specific survival (DSS) in endometrioid ECs (EECs). The objectives of this study were to investigate the spatial expression of FGFR2b in normal and hyperplasia with and without atypia of human endometrium and to assess the prognostic significance of FGFR2b expression in EC. FGFR2b and FGFR2c mRNA expression was evaluated in normal (proliferative [n = 10], secretory [n = 15], and atrophic [n = 10] endometrium), hyperplasia with and without atypia (n = 19) as well as two patient cohorts of EC samples (discovery [n = 78] and Vancouver [n = 460]) using isoform‐specific BaseScope RNA in situ hybridization assays. Tumors were categorized based on FGFR2 isoform expression (one, both, or neither) and categories were correlated with clinicopathologic markers, molecular subtypes, and clinical outcomes. The FGFR2b splice isoform was exclusively expressed in the epithelial compartment of normal endometrium and hyperplasia without atypia. We observed FGFR2c expression at the basalis layer of glands in 33% (3/9) of hyperplasia with atypia. In patients with EEC, FGFR2b+/FGFR2c− expression was found in 48% of the discovery cohort and 35% of the validation Vancouver cohort. In univariate analyses, tumors with FGFR2b+/FGFR2c− expression had longer PFS (hazard ratio [HR] 0.265; 95% CI 0.145–0.423; log‐rank p < 0.019) and DSS (HR 0.31; 95% CI 0.149–0.622; log‐rank p < 0.001) compared to tumors with FGFR2b−/FGFR2c+ expression in the large EEC Vancouver cohort. In multivariable Cox regression analyses, tumors with FGFR2b+/FGFR2c− expression were significantly associated with longer DSS (HR 0.37; 95% CI 0.153–0.872; log‐rank p < 0.023) compared to FGFR2b−/FGFR2c+ tumors. In conclusion, FGFR2b+/FGFR2c− expression is associated with favorable clinicopathologic markers and clinical outcomes suggesting that FGFR2b could play a role in tailoring the management of EEC patients in the clinic if these findings are confirmed in an independent cohort. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Identifying therapies to combat epithelial mesenchymal plasticity-associated chemoresistance to conventional breast cancer therapies using an shRNA library screen

Author

Bhatia, Sugandha, Blick, Tony, Pinto, Cletus, Waltham, Mark, Monkman, James, Ivanova, Ekaterina, Pollock, Pamela M, Nagaraj, Shivashankar H, Wiegmans, Adrian P, Haviv, Izhak, Simpson, Kaylene J, Thompson, Erik W, Bhatia, Sugandha, Blick, Tony, Pinto, Cletus, Waltham, Mark, Monkman, James, Ivanova, Ekaterina, Pollock, Pamela M, Nagaraj, Shivashankar H, Wiegmans, Adrian P, Haviv, Izhak, Simpson, Kaylene J, and Thompson, Erik W

Abstract

Background: Breast cancer (BC) is a heterogeneous disease for which the commonly used chemotherapeutic agents primarily include the anthracyclines (doxorubicin, epirubicin), microtubule inhibitors (paclitaxel, docetaxel, eribulin), and alkylating agents (cyclophosphamide). While these drugs can be highly effective, metastatic tumours are frequently refractory to treatment or become resistant upon tumour relapse. Methods: We undertook a cell polarity/epithelial mesenchymal plasticity (EMP)-enriched short hairpin RNA (shRNA) screen in MDA-MB-468 breast cancer cells to identify factors underpinning heterogeneous responses to three chemotherapeutic agents used clinically in breast cancer: Doxorubicin, docetaxel, and eribulin. shRNA-transduced cells were treated for 6 weeks with the EC10 of each drug, and shRNA representation assessed by deep sequencing. We first identified candidate genes with depleted shRNA, implying that their silencing could promote a response. Using the Broad Institute’s Connectivity Map (CMap), we identified partner inhibitors targeting the identified gene families that may induce cell death in combination with doxorubicin, and tested them with all three drug treatments. Results: In total, 259 shRNAs were depleted with doxorubicin treatment (at p < 0.01), 66 with docetaxel, and 25 with eribulin. Twenty-four depleted hairpins overlapped between doxorubicin and docetaxel, and shRNAs for TGFB2, RUNX1, CCDC80, and HYOU1 were depleted across all the three drug treatments. Inhibitors of MDM/TP53, TGFBR, and FGFR were identified by CMap as the top pharmaceutical perturbagens and we validated the combinatorial benefits of the TGFBR inhibitor (SB525334) and MDM inhibitor (RITA) with doxorubicin treatment, and also observed synergy between the inhibitor SB525334 and eribulin in MDA-MB-468 cells. Conclusions: Taken together, a cell polarity/EMP-enriched shRNA library screen identifi

Published
2020

42. FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes

Author

Sengal, Asmerom T., Patch, Ann-Marie, Snell, Cameron E., Smith, Deborah S., Leung, Samuel C.Y., Talhouk, Aline, Williams, Elizabeth D., McAlpine, Jessica N., Pollock, Pamela M., Sengal, Asmerom T., Patch, Ann-Marie, Snell, Cameron E., Smith, Deborah S., Leung, Samuel C.Y., Talhouk, Aline, Williams, Elizabeth D., McAlpine, Jessica N., and Pollock, Pamela M.

Abstract

Purpose: The two most common molecular subtypes of endometrial cancers, mismatch repair deficient (MMRd) and p53 wild-type (p53wt) comprise the majority of endometrial cancers and have intermediate prognoses where additional risk stratification biomarkers are needed. Isoform switching of FGFR2 from FGFR2b to FGFR2c (normally expressed in mesenchymal cells), has been reported in other solid carcinomas. The objective of this study was to investigate the role of FGFR2c in risk stratification of endometrial cancer. Experimental Design: We have developed and optimized a BaseScope RNA ISH assay to detect FGFR2c. FGFR2c expression was determined in a preliminary screening cohort of 78 endometrial cancers and a clinically and molecularly annotated Vancouver cohort (n ¼ 465). Cox regression model analyses were performed to assess the prognostic value of FGFR2c. Results: Univariate and multivariate analyses revealed FGFR2c expression was significantly associated with shorter disease-specific survival (DSS) and progression-free survival (PFS) in endometrioid endometrial cancer (EEC, n ¼ 302). Notably, FGFR2c expression was significantly associated with shorter PFS and DSS in patients with grade 3 EECs (P < 0.003 and P < 0.002) and the European Society Medical Oncology (ESMO) high-risk group (P < 0.0001 and P < 0.002), respectively. Moreover, within the MMRd subtype, FGFR2c expression was significantly associated with shorter PFS (P < 0.048) and DSS (P < 0.001). Conclusions: FGFR2c expression appears an independent prognostic biomarker in patients with EEC and further discerns the outcomes within grade 3 tumors, ESMO high-risk groups, as well as within the MMRd and p53wt subtypes. FGFR2c inclusion into future molecular subtyping can further refine risk stratification of EEC.

Published
2020

43. Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer

Author

Harrington, Brittney S., He, Yaowu, Khan, Tashbib, Puttick, Simon, Conroy, Paul J., Kryza, Thomas, Cuda, Tahleesa, Sokolowski, Kamil A., Tse, Brian W.C., Robbins, Katherine K., Arachchige, Buddhika J., Stehbens, Samantha J., Pollock, Pamela M., Reed, Sarah, Weroha, S. John, Haluska, Paul, Salomon, Carlos, Lourie, Rohan, Perrin, Lewis C., Law, Ruby H.P., Whisstock, James C., Hooper, John D., Harrington, Brittney S., He, Yaowu, Khan, Tashbib, Puttick, Simon, Conroy, Paul J., Kryza, Thomas, Cuda, Tahleesa, Sokolowski, Kamil A., Tse, Brian W.C., Robbins, Katherine K., Arachchige, Buddhika J., Stehbens, Samantha J., Pollock, Pamela M., Reed, Sarah, Weroha, S. John, Haluska, Paul, Salomon, Carlos, Lourie, Rohan, Perrin, Lewis C., Law, Ruby H.P., Whisstock, James C., and Hooper, John D.

Abstract

CUB-domain containing protein 1 (CDCP1) is a cancer associated cell surface protein that amplifies pro-tumorigenic signalling by other receptors including EGFR and HER2. Its potential as a cancer target is supported by studies showing that anti-CDCP1 antibodies inhibit cell migration and survival in vitro, and tumor growth and metastasis in vivo. Here we characterize two anti-CDCP1 antibodies, focusing on immuno-conjugates of one of these as a tool to detect and inhibit ovarian cancer.Methods: A panel of ovarian cancer cell lines was examined for cell surface expression of CDCP1 and loss of expression induced by anti-CDCP1 antibodies 10D7 and 41-2 using flow cytometry and Western blot analysis. Surface plasmon resonance analysis and examination of truncation mutants was used to analyse the binding properties of the antibodies for CDCP1. Live-cell spinning-disk confocal microscopy of GFP-tagged CDCP1 was used to track internalization and intracellular trafficking of CDCP1/antibody complexes. In vivo, zirconium 89-labelled 10D7 was detected by positron-emission tomography imaging, of an ovarian cancer patient-derived xenograft grown intraperitoneally in mice. The efficacy of cytotoxin-conjugated 10D7 was examined against ovarian cancer cells in vitro and in vivo.Results: Our data indicate that each antibody binds with high affinity to the extracellular domain of CDCP1 causing rapid internalization of the receptor/antibody complex and degradation of CDCP1 via processes mediated by the kinase Src. Highlighting the potential clinical utility of CDCP1, positron-emission tomography imaging, using zirconium 89-labelled 10D7, was able to detect subcutaneous and intraperitoneal xenograft ovarian cancers in mice, including small (diameter <3 mm) tumor deposits of an ovarian cancer patient-derived xenograft grown intraperitoneally in mice. Furthermore, cytotoxin-conjugated 10D7 was effective at inhibiting growth of CDCP1-expressing ovarian cancer cells in vitro and in vivo.Conc

Published
2020

44. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy

Author

Leon-Castillo, Alicia, De Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda R., Mackay, Helen J., Leary, Alexandra, Nijman, Hans W., Singh, Naveena, Pollock, Pamela M., Bessette, Paul, Fyles, Anthony, Haie-Meder, Christine, Smit, Vincent T.H.B.M., Edmondson, Richard J., Putter, Hein, Kitchener, Henry C., Crosbie, Emma J., De Bruyn, Marco, Nout, Remi A., Horeweg, Nanda, Creutzberg, Carien L., Bosse, Tjalling, Leon-Castillo, Alicia, De Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda R., Mackay, Helen J., Leary, Alexandra, Nijman, Hans W., Singh, Naveena, Pollock, Pamela M., Bessette, Paul, Fyles, Anthony, Haie-Meder, Christine, Smit, Vincent T.H.B.M., Edmondson, Richard J., Putter, Hein, Kitchener, Henry C., Crosbie, Emma J., De Bruyn, Marco, Nout, Remi A., Horeweg, Nanda, Creutzberg, Carien L., and Bosse, Tjalling

Abstract

PURPOSE: The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) for women with high-risk endometrial cancer (EC). Because The Cancer Genome Atlas defined an EC molecular classification with strong prognostic value, we investigated prognosis and impact of chemotherapy for each molecular subgroup using tissue samples from PORTEC-3 trial participants. METHODS: Paraffin-embedded tissues of 423 consenting patients were collected. Immunohistochemistry for p53 and mismatch repair (MMR) proteins, and DNA sequencing for POLE exonuclease domain were done to classify tumors as p53 abnormal (p53abn), POLE-ultramutated (POLEmut), MMR-deficient (MMRd), or no specific molecular profile (NSMP). The primary end point was recurrence-free survival (RFS). Kaplan-Meier method, log-rank test, and Cox model were used for analysis. RESULTS: Molecular analysis was successful in 410 high-risk EC (97%), identifying the 4 subgroups: P53abn EC (n = 93; 23%), POLEmut (n = 51; 12%), MMRd (n = 137; 33%), and NSMP (n = 129; 32%). Five-year RFS was 48% for patients with p53abn EC, 98% for POLEmut EC, 72% for MMRd EC, and 74% for NSMP EC (P <001). The 5-year RFS with CTRT versus RT for p53abn EC was 59% versus 36% (P =019); 100% versus 97% for patients with POLEmut EC (P =637); 68% versus 76% (P =428) for MMRd EC; and 80% versus 68% (P =243) for NSMP EC. CONCLUSION: Molecular classification has strong prognostic value in high-risk EC, with significantly improved RFS with adjuvant CTRT for p53abn tumors, regardless of histologic type. Patients with POLEmut EC had an excellent RFS in both trial arms. EC molecular classification should be incorporated in the risk stratification of these patients as well as in future trials to target specific subgrou

Published
2020

45. Microarray expression profiling in melanoma reveals a BRAF mutation signature

Author

Pavey, Sandra, Johansson, Peter, Packer, Leisl, Taylor, Jennifer, Stark, Mitchell, Pollock, Pamela M, Walker, Graeme J, Boyle, Glen M, Harper, Ursula, Cozzi, Sarah-Jane, Hansen, Katherine, Yudt, Laura, Schmidt, Chris, Hersey, Peter, Ellem, Kay AO, O'Rourke, Michael GE, Parsons, Peter G, Meltzer, Paul, Ringnér, Markus, and Hayward, Nicholas K

Published
2004
Full Text
View/download PDF

46. Integrated genomic characterization of endometrial carcinoma

Author

Getz, Gad, Gabriel, Stacey B., Cibulskis, Kristian, Lander, Eric, Sivachenko, Andrey, Sougnez, Carrie, Lawrence, Mike, Kandoth, Cyriac, Dooling, David, Fulton, Robert, Fulton, Lucinda, Kalicki-Veizer, Joelle, McLellan, Michael D., OʼLaughlin, Michelle, Schmidt, Heather, Wilson, Richard K., Ye, Kai, Ding, Li, Mardis, Elaine R., Ally, Adrian, Balasundaram, Miruna, Birol, Inanc, Butterfield, Yaron S. N., Carlsen, Rebecca, Carter, Candace, Chu, Andy, Chuah, Eric, Chun, Hye-Jung E., Dhalla, Noreen, Guin, Ranabir, Hirst, Carrie, Holt, Robert A., Jones, Steven J. M., Lee, Darlene, Li, Haiyan I., Marra, Marco A., Mayo, Michael, Moore, Richard A., Mungall, Andrew J., Plettner, Patrick, Schein, Jacqueline E., Sipahimalani, Payal, Tam, Angela, Varhol, Richard J., Gordon Robertson, A., Cherniack, Andrew D., Pashtan, Itai, Saksena, Gordon, Onofrio, Robert C., Schumacher, Steven E., Tabak, Barbara, Carter, Scott L., Hernandez, Bryan, Gentry, Jeff, Salvesen, Helga B., Ardlie, Kristin, Winckler, Wendy, Beroukhim, Rameen, Meyerson, Matthew, Hadjipanayis, Angela, Lee, Semin, Mahadeshwar, Harshad S., Park, Peter, Protopopov, Alexei, Ren, Xiaojia, Seth, Sahil, Song, Xingzhi, Tang, Jiabin, Xi, Ruibin, Yang, Lixing, Zeng, Dong, Kucherlapati, Raju, Chin, Lynda, Zhang, Jianhua, Todd Auman, J., Balu, Saianand, Bodenheimer, Tom, Buda, Elizabeth, Neil Hayes, D., Hoyle, Alan P., Jefferys, Stuart R., Jones, Corbin D., Meng, Shaowu, Mieczkowski, Piotr A., Mose, Lisle E., Parker, Joel S., Perou, Charles M., Roach, Jeff, Shi, Yan, Simons, Janae V., Soloway, Mathew G., Tan, Donghui, Topal, Michael D., Waring, Scot, Wu, Junyuan, Hoadley, Katherine A., Baylin, Stephen B., Bootwalla, Moiz S., Lai, Phillip H., Triche, Timothy J., Jr, Van Den Berg, David J., Weisenberger, Daniel J., Laird, Peter W., Shen, Hui, Cho, Juok, DiCara, Daniel, Frazer, Scott, Heiman, David, Jing, Rui, Lin, Pei, Mallard, Will, Stojanov, Petar, Voet, Doug, Zhang, Hailei, Zou, Lihua, Noble, Michael, Reynolds, Sheila M., Shmulevich, Ilya, Arman Aksoy, B., Antipin, Yevgeniy, Ciriello, Giovanni, Dresdner, Gideon, Gao, Jianjiong, Gross, Benjamin, Jacobsen, Anders, Ladanyi, Marc, Reva, Boris, Sander, Chris, Sinha, Rileen, Onur Sumer, S., Taylor, Barry S., Cerami, Ethan, Weinhold, Nils, Schultz, Nikolaus, Shen, Ronglai, Benz, Stephen, Goldstein, Ted, Haussler, David, Ng, Sam, Szeto, Christopher, Stuart, Joshua, Benz, Christopher C., Yau, Christina, Zhang, Wei, Annala, Matti, Broom, Bradley M., Casasent, Tod D., Ju, Zhenlin, Liang, Han, Liu, Guoyan, Lu, Yiling, Unruh, Anna K., Wakefield, Chris, Weinstein, John N., Zhang, Nianxiang, Liu, Yuexin, Broaddus, Russell, Akbani, Rehan, Mills, Gordon B., Adams, Christopher, Barr, Thomas, Black, Aaron D., Bowen, Jay, Deardurff, John, Frick, Jessica, Gastier-Foster, Julie M., Grossman, Thomas, Harper, Hollie A., Hart-Kothari, Melissa, Helsel, Carmen, Hobensack, Aaron, Kuck, Harkness, Kneile, Kelley, Leraas, Kristen M., Lichtenberg, Tara M., McAllister, Cynthia, Pyatt, Robert E., Ramirez, Nilsa C., Tabler, Teresa R., Vanhoose, Nathan, White, Peter, Wise, Lisa, Zmuda, Erik, Barnabas, Nandita, Berry-Green, Charlenia, Blanc, Victoria, Boice, Lori, Button, Michael, Farkas, Adam, Green, Alex, MacKenzie, Jean, Nicholson, Dana, Kalloger, Steve E., Blake Gilks, C., Karlan, Beth Y., Lester, Jenny, Orsulic, Sandra, Borowsky, Mark, Cadungog, Mark, Czerwinski, Christine, Huelsenbeck-Dill, Lori, Iacocca, Mary, Petrelli, Nicholas, Rabeno, Brenda, Witkin, Gary, Nemirovich-Danchenko, Elena, Potapova, Olga, Rotin, Daniil, Berchuck, Andrew, Birrer, Michael, DiSaia, Phillip, Monovich, Laura, Curley, Erin, Gardner, Johanna, Mallery, David, Penny, Robert, Dowdy, Sean C., Winterhoff, Boris, Dao, Linda, Gostout, Bobbie, Meuter, Alexandra, Teoman, Attila, Dao, Fanny, Olvera, Narciso, Bogomolniy, Faina, Garg, Karuna, Soslow, Robert A., Levine, Douglas A., Abramov, Mikhail, Bartlett, John M. S., Kodeeswaran, Sugy, Parfitt, Jeremy, Moiseenko, Fedor, Clarke, Blaise A., Goodman, Marc T., Carney, Michael E., Matsuno, Rayna K., Fisher, Jennifer, Huang, Mei, Kimryn Rathmell, W., Thorne, Leigh, Van Le, Linda, Dhir, Rajiv, Edwards, Robert, Elishaev, Esther, Zorn, Kristin, Goodfellow, Paul J., Mutch, David, Kahn, Ari B., Bell, Daphne W., Pollock, Pamela M., Wang, Chen, A.Wheeler, David, Shinbrot, Eve, Ayala, Brenda, Chu, Anna L., Jensen, Mark A., Kothiyal, Prachi, Pihl, Todd D., Pontius, Joan, Pot, David A., Snyder, Eric E., Srinivasan, Deepak, Mills Shaw, Kenna R., Sheth, Margi, Davidsen, Tanja, Eley Martin L. Ferguson, Greg, Demchok, John A., Yang, Liming, Guyer, Mark S., Ozenberger, Bradley A., and Sofia, Heidi J.

Published
2013
Full Text
View/download PDF

48. Identifying Therapies to Combat Epithelial Mesenchymal Plasticity-Associated Chemoresistance to Conventional Breast Cancer Therapies Using An shRNA Library Screen

Author

Bhatia, Sugandha, primary, Blick, Tony, additional, Pinto, Cletus, additional, Waltham, Mark, additional, Monkman, James, additional, Ivanova, Ekaterina, additional, Pollock, Pamela M., additional, Nagaraj, Shivashankar H., additional, Wiegmans, Adrian P., additional, Haviv, Izhak, additional, Simpson, Kaylene J., additional, and Thompson, Erik W., additional

Published
2020
Full Text
View/download PDF

49. Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer

Author

Harrington, Brittney S., primary, He, Yaowu, additional, Khan, Tashbib, additional, Puttick, Simon, additional, Conroy, Paul J., additional, Kryza, Thomas, additional, Cuda, Tahleesa, additional, Sokolowski, Kamil A, additional, Tse, Brian WC, additional, Robbins, Katherine K., additional, Arachchige, Buddhika J., additional, Stehbens, Samantha J., additional, Pollock, Pamela M., additional, Reed, Sarah, additional, Weroha, S. John, additional, Haluska, Paul, additional, Salomon, Carlos, additional, Lourie, Rohan, additional, Perrin, Lewis C., additional, Law, Ruby H. P., additional, Whisstock, James C., additional, and Hooper, John D, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results